The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InGerman medical packaging manufacturer Gerresheimer has announced a second postponement of its 2025 annual financial results, now rescheduled for June. The delay stems from an ongoing investigation into specific business transactions, which has prevented the timely finalization of its accounts. Consequently, Deutsche Boerse will remove the company from the SDAX index in accordance with transparency and reporting regulations. This exclusion is expected to trigger significant selling pressure from passive funds and ETFs tracking the index. Investors remain concerned about the potential findings of the probe and its impact on corporate governance. The stock is likely to face continued volatility until the investigation concludes and financial clarity is restored.